コンテンツへスキップ
Merck

スキップする

1A03400

USP

Bortezomib L-Phenylalanyl Analog

Pharmaceutical Analytical Impurity (PAI)

別名:

Bortezomib L-Phenylalanyl Analog, (((R)-3-METHYL-1-((S)-3-PHENYL-2-((S)-3-PHENYL-2-(PYRAZINE-2-CARBOXAMIDO)PROPANAMIDO)PROPANAMIDO)BUTYL)BORONIC ACID)

ログインで組織・契約価格をご覧ください。

サイズを選択してください

表示を変更する
サイズ/SKU在庫状況単価

この商品について

実験式(ヒル表記法):
C28H34BN5O5
CAS番号:
分子量:
531.41
MDL number:
NACRES:
NA.24
UNSPSC Code:
41116107
eCl@ss:
25140904
現在、価格および在庫状況を閲覧できません。
テクニカルサービス
お困りのことがあれば、経験豊富なテクニカルサービスチームがお客様をサポートします。
お手伝いします


grade

pharmaceutical analytical impurity (PAI)

agency

USP

API family

bortezomib

manufacturer/tradename

USP

application(s)

pharmaceutical
pharmaceutical
pharmaceutical small molecule

format

neat

storage temp.

2-8°C

General description

Find answers to frequently asked questions on USP products in USP FAQs.
Bortezomib L-Phenylalanyl Analog is a USP Pharmaceutical Analytical Impurity (PAI).


USP PAI are a product line of impurities suitable for research and analytical purposes, which help to ensure the quality and safety of medicines.


Associated Drug Substance: Bortezomib


Therapeutic Area: Oncology

Application

Bortezomib L-Phenylalanyl Analog (USP PAI) is intended for use in analytical testing to detect, identify, and measure pharmaceutical impurities.

Features and Benefits

USP PAI advance your early analytical R&D and process development. PAI can be used in the following applications:
1. Conduct analytical tests during early formulation feasibility studies.
2. Determine degradation impurities produced during stress studies.
3. Develop, validate, and transfer analytical methods.
4. Perform spiking studies during process R&D to demonstrate depletion upon recrystallization.
5. Record retention times and/or spectra
6. Determine relative response factors.
7. Identify unknown impurities that formed during ICH stability conditions.
8. Identify impurities that are present in the Reference Listed Drug
9. Test for and profile impurities not listed in drug substance and drug product monographs.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  

Other Notes

Sales restrictions may apply.
USP issued SDS can be found here

類似品目との比較

比較内容をすべて表示

相違点を表示

1 of 1

当該品目
1A037701A03780PHR8455
vibrant-m

PHR8455

Bortezomib

description

Pharmaceutical Analytical Impurity (PAI)

description

Pharmaceutical Analytical Impurity (PAI)

description

Pharmaceutical Analytical Impurity (PAI)

description

pkg of 100 mg, certified reference material, pharmaceutical secondary standard

manufacturer/tradename

USP

manufacturer/tradename

USP

manufacturer/tradename

USP

manufacturer/tradename

-

grade

pharmaceutical analytical impurity (PAI)

grade

pharmaceutical analytical impurity (PAI)

grade

pharmaceutical analytical impurity (PAI)

grade

pharmaceutical secondary standard, certified reference material

application(s)

pharmaceutical
pharmaceutical
pharmaceutical small molecule

application(s)

pharmaceutical small molecule

application(s)

pharmaceutical small molecule

application(s)

pharmaceutical

format

neat

format

neat

format

neat

format

neat

API family

bortezomib

API family

-

API family

-

API family

bortezomib

agency

USP

agency

USP

agency

USP

agency

(Not traceable to any primary pharmacopeia standard)


ピクトグラム

Health hazardExclamation mark

注意喚起語

Warning

ハザードコード

Hazard Classifications

Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT RE 2

標的臓器

Gastro-intestinal system

保管分類

11 - Combustible Solids

一体何が起きているの?

WGK 3

引火点 (F)

Not applicable

引火点(°C)

Not applicable



最新バージョンのいずれかを選択してください:

試験成績書(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 資料 section.

サポートが必要な場合は、お問い合わせください カスタマーサポート

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする